Transarterial Chemoembolization Combined with Radiofrequency Ablation in the Treatment of Stage B1 Intermediate Hepatocellular Carcinoma

Table 4

Subgroup analysis of survivals.

	TACE-RFA				TACE				value
	1-year (%)	3-year (%)	5-year (%)	Median time (months)	1-year (%)	3-year (%)	5-year (%)	Median time (months)
Overall survival
Tumor size ≤3 cm	88.8	51.3	30.8	37.6	80.5	31.8	23.8	26.0	0.024
Tumor size >3 cm	75.0	37.9	14.3	29.8	75.5,	18.8	11.0	19.0	0.053
Single tumor	86.2	53.9	28.4	37.8	75.2	27.1	17.6	23.0	0.016
Multiple tumors	82.8	42.7	23.4	29.8	73.5	26.0	13.6	22.0	0.051
Progression-free survival
Tumor size ≤3 cm	75.2	32.1	15.3	21.9	66.6	14.9	3.1	15.0	<0.001
Tumor size >3 cm	66.7	18.4	9.9	18.0	54.8	8.7	0	13.0	0.008
Single tumor	79.3	31.9	17.2	21.0	59.7	14.3	4.8	14.2	0.001
Multiple tumors	69.5	24.5	11.6	19.0	55.9	9.4	0	13.8	<0.001

TACE: transarterial chemoembolization; RFA: radiofrequency ablation.